Athira Pharma Inc. (ATHA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Athira Pharma Inc. (ATHA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.53

-0.00 (-0.21%)

At close: Jan 14, 2025, 3:59 PM

0.53

-0.09%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	0.52
Market Cap	20.59M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.84
PE Ratio (ttm)	-0.19
Forward PE	n/a
Analyst	Hold

Ask	0.6
Volume	95,978
Avg. Volume (20D)	4,885,731
Open	0.53
Previous Close	0.53
Day's Range	0.52 - 0.57
52-Week Range	0.41 - 4.30
Beta	undefined

About ATHA

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkins...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 18, 2020

Employees 65

Stock Exchange NASDAQ

Ticker Symbol ATHA

Website https://www.athira.com

Analyst Forecast

According to 4 analyst ratings, the average rating for ATHA stock is "Hold." The 12-month stock price forecast is $11.25, which is an increase of 2012.68% from the latest price.

Buy 25.00%

Hold 75.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-12.01%

Althira Pharma shares are trading lower after the ... Unlock content with Pro Subscription

2 months ago · Source

+15.73%

Athira Pharma shares are trading higher after the company announced it will present results from its Phase 2/3 LIFT-AD clinical trial of Fosgonimeton to treat Alzheimer's disease.

News

1 week ago · geekwire.com

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Seattle-area biotech company Athira Pharma agreed to pay $4.

1 month ago · proactiveinvestors.com

ATHA Energy identifies high-grade uranium mineralization in new outcrops at Angilak

ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) said it has uncovered numerous outcrops hosting high-grade uranium mineralization at Angilak in Nunavut. The surficial mapping program, centered around the L...

1 month ago · proactiveinvestors.com

ATHA Energy reveals updated technical report for Angilak uranium project

ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) has unveiled its updated 2024 technical report for its 100%-owned Angilak uranium project in Nunavut. The third-party updated technical report establishes a ...

2 months ago · proactiveinvestors.com

ATHA Energy appoints seasoned experts to leadership team

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has announced the appointment of Erinn Broshko as a non-executive director and Rhéal Assié as chief financial officer, starting November 6. The company said Br...